AIM
APGE icon

AXA Investment Managers’s Apogee Therapeutics APGE Stock Holding History

AXA Investment Managers’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$976K Buy
+24,554
New +$938K ﹤0.01% 901

Other funds holding APGE

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

AXA Investment Managers's APGE Position: Q3 2025 in Review

AXA Investment Managers opened a new position in Apogee Therapeutics (APGE) in Q3 2025: 24,554 shares worth $976K. The stake represents ﹤0.01% of the portfolio and ranks #901 among its holdings.

174 funds tracked by Wall St. Rank hold APGE as of Q3 2025.

  • AXA Investment Managers held 24,554 shares of Apogee Therapeutics worth $976K as of Q3 2025.
  • Apogee Therapeutics was a new AXA Investment Managers position in Q3 2025.
  • Apogee Therapeutics made up ﹤0.01% of AXA Investment Managers's portfolio in Q3 2025, its #901 holding.
  • 174 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2025.

Based on AXA Investment Managers's 13F filing for Q3 2025, filed 14 Nov 2025.